AstraZeneca adds to immuno-oncology leadership team

31 July 2017

AstraZeneca (LSE: AZN) and its research arm MedImmune, today announced the appointment of two internationally-recognized immuno-oncology leaders.

Dr Jean-Charles Soria joins MedImmune as senior vice president, head of oncology innovative medicines, and Dr Geoffrey Kim has been appointed as head of oncology strategic combinations at AstraZeneca.

Dr Bahija Jallal, executive VP MedImmune, said: “AstraZeneca and MedImmune are delighted to welcome Dr Soria and Dr Kim. Our ability to attract these recognized experts in the fast-developing field of immuno-oncology speaks to our exciting pipeline of innovative cancer treatments and our commitment to pushing the boundaries of science.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK